Analysts at Cantor Fitzgerald Reiterate their Past ‘”Buy”’ rating on Shares Abeona Therapeutics (NASDAQ:ABEO), Set a $36.0000 Price Target

May 17, 2018 - By Kurt Siggers

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

Abeona Therapeutics (NASDAQ:ABEO) Rating Reaffirmed

Abeona Therapeutics (NASDAQ:ABEO) just had their share rating of a ‘”Buy”‘ issued by research analysts at Cantor Fitzgerald, who now has a $36.0000 TP on the $993.41M market cap company or a 71.43 % upside potential. This key information was released in analysts note on Tuesday morning.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 4 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics has $36.0 highest and $26.0 lowest target. $30’s average target is 42.86% above currents $21 stock price. Abeona Therapeutics had 14 analyst reports since November 21, 2017 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, May 3. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by H.C. Wainwright on Thursday, February 8. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, November 22 report. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, January 29. The firm has “Buy” rating by Cantor Fitzgerald given on Wednesday, February 7. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, January 4. The rating was maintained by Jefferies with “Buy” on Tuesday, November 21. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, March 20. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, February 1. The company was maintained on Tuesday, January 23 by RBC Capital Markets.

The stock increased 2.44% or $0.5 during the last trading session, reaching $21. About 780,550 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 188.66% since May 17, 2017 and is uptrending. It has outperformed by 177.11% the S&P500.

Analysts await Abeona Therapeutics Inc. (NASDAQ:ABEO) to report earnings on August, 21. They expect $-0.20 earnings per share, up 4.76 % or $0.01 from last year’s $-0.21 per share. After $-0.18 actual earnings per share reported by Abeona Therapeutics Inc. for the previous quarter, Wall Street now forecasts 11.11 % negative EPS growth.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $993.41 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

More notable recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: which released: “Krystal Biotech: Important Catalyst And Value Inflection Point Approaching” on May 08, 2018, also with their article: “Abeona Therapeutics (ABEO) Tops Q1 EPS by 1c” published on May 11, 2018, published: “Genomic Medicine: Catch The Gene Therapy Wave” on May 14, 2018. More interesting news about Abeona Therapeutics Inc. (NASDAQ:ABEO) were released by: and their article: “Abeona Therapeutics (ABEO) Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of …” published on May 14, 2018 as well as‘s news article titled: “Abeona Therapeutics Announces Upcoming Presentations” with publication date: May 08, 2018.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.